Tilray Brands (TLRY) Income from Continuing Operations (2017 - 2026)
Tilray Brands' (TLRY) quarterly Income from Continuing Operations came in at 29636000.0 in Q2 2026, up 96.73% YoY from 15064604.42 in Q2 2025, and down 17.45% on a QoQ basis from 25233000.0 in Q1 2026.
Tilray Brands (TLRY) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Tilray Brands (TLRY) has 10 years of Income from Continuing Operations data on file, last reported at 29636000.0 in Q2 2026.
- Quarterly Income from Continuing Operations rose 96.73% year-over-year to 29636000.0 in Q2 2026, while the trailing twelve-month figure through May 2026 was 96865000.0 (up 94.67% YoY) and the FY2026 annual result came in at 96865000.0, up 94.67% from the prior year.
- Income from Continuing Operations slipped to 29636000.0 in Q2 2026, from 25233000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 177538000.0 in Q2 2023 to a low of 1195752000.0 in Q1 2023.
- A 5-year average of 200089944.44 and a median of 51023000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations soared 147.75% — and 2025, when it tumbled 9797.92%.
- Tracing TLRY's Income from Continuing Operations over 5 years: stood at 85061000.0 in 2022, then jumped by 45.71% to 46183000.0 in 2023, then sank by 84.65% to 85275000.0 in 2024, then jumped by 48.98% to 43509000.0 in 2025, then jumped by 31.89% to 29636000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 29636000.0 (Q2 2026), 25233000.0 (Q1 2026), and 43509000.0 (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Tilray Brands | 512.33 Mn | 277.70 Mn | 90.52 Mn | -29.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | -29.64 Mn |
| Feb 28, 2026 | -25.23 Mn |
| Nov 30, 2025 | -43.51 Mn |
| Aug 31, 2025 | 1.51 Mn |
| May 31, 2025 | -905.20 Mn |
| Feb 28, 2025 | -793.53 Mn |
| Nov 30, 2024 | -85.28 Mn |
| Aug 31, 2024 | -34.65 Mn |
| May 31, 2024 | 9.33 Mn |
| Feb 29, 2024 | -104.98 Mn |
| Nov 30, 2023 | -46.18 Mn |
| Aug 31, 2023 | -55.86 Mn |
| May 31, 2023 | 177.54 Mn |
| Feb 28, 2023 | -1.20 Bn |
| Nov 30, 2022 | -85.06 Mn |
| Aug 31, 2022 | -65.79 Mn |
| May 31, 2022 | -371.80 Mn |
| Feb 28, 2022 | 52.48 Mn |
| Nov 30, 2021 | 5.80 Mn |
| Aug 31, 2021 | -34.60 Mn |